To the Editor A recent Viewpoint1 in JAMA Oncology defends maintaining the 340B Drug Pricing Program under its current form despite widespread fraud and abuse. Established by Congress in 1992, the 340B Drug Pricing Program requires pharmaceutical manufacturers to supply sharply discounted drugs to health care facilities that serve high volumes of poor, indigent, uninsured, or otherwise vulnerable patients.2
Fong WH. 340B Drug Pricing Program Reform. JAMA Oncol. 2016;2(3):403. doi:10.1001/jamaoncol.2015.5400
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: